Lung Cancer

Giorgio Scagliotti, MD, PhD, professor of Medical Oncology, University of Torino, discusses the design and the results of the phase III ASCEND-5 study during an interview at the 2016 ESMO Congress.

The addition of pembrolizumab (Keytruda) to frontline platinum-based chemotherapy for advanced non–small cell lung cancer almost doubled the response rate compared with chemotherapy alone.

Ignacio I. Wistuba, MD, chair, Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, Anderson Clinical Faculty Chair for Cancer Treatment and Research, The University of Texas MD Anderson Cancer Center, discusses how pathologists maximize outcomes with limited tissue in patients with lung cancer.

First-line therapy with nivolumab failed to improve progression-free survival in PD-L1 positive non-small cell lung cancer compared with standard chemotherapy.

Atezolizumab (Tecentriq) reduced the risk of death by 27% compared with docetaxel in patients with advanced non–small cell lung cancer following the failure of platinum-based chemotherapy.

Progression-free survival was more than 3 times longer with ceritinib (Zykadia) than with chemotherapy, the current second-line standard, in patients with advanced ALK-positive non–small cell lung cancer who progressed after first-line crizotinib.

Single-agent pembrolizumab improved overall and progression-free survival compared with doublet chemotherapy for untreated patients with advanced non–small cell lung cancer who expressed PD-L1 on ≥50% of cells.

Lars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses the use of lenvatinib to treat patients with non-small cell lung cancer at the 2016 ESMO Congress.

Almost 40% of patients with resected early-stage non–small cell lung cancer had evidence of tumor regression following neoadjuvant treatment with nivolumab (Opdivo) in a preliminary clinical trial.

Tracey L. Evans, MD, shares her perspective on the role of PD-L1 testing in lung cancer. She also discusses the role of liquid biopsies and other assays that could possibly be on the horizon.

Hossein Borghaei, DO, provides additional insight on checkpoint inhibitors, determining patient selection, and how these therapies will continue to significantly impact the treatment landscape in non–small cell lung cancer for years to come.

Kevin Stephans, MD, associate staff, Radiation Oncology at Cleveland Clinic, discusses advancements in the treatment of patients with oligometastatic lung cancer.

The FDA has granted a breakthrough therapy designation to alectinib (Alecensa) as a frontline treatment for patients with ALK-positive non–small cell lung cancer.

Todd Bauer, MD, associate director, Drug Development, Sarah Cannon Research Institute, discusses the emergence of the novel agent rovalpituzumab tesirine in the treatment of patients with small cell lung cancer in an interview during the IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology.

From optimal therapies for patients with non-driver adenocarcinoma, to studying the biology of squamous cell non–small cell lung cancer, to exploring novel combination regimens, to predicting the risk of mortality, the field of lung cancer is undergoing tremendous changes, explained Corey J. Langer, MD.

Nathan Pennell, MD, PhD, medical oncologist, Department of Hematology and Oncology, Cleveland Clinic, discusses some of the rare toxicities seen in patients with lung cancer.

Robert Pirker, MD, Department of Medicine I, Medical University of Vienna, discusses novel clinical trial designs that researchers should use going forward in lung cancer.

Joshua Bauml, MD, discusses the evolution of EGFR-targeted therapies, resistance mutations in patients with non–small cell lung cancer, the evolution of next-generation sequencing, and ongoing trials that could have an impact in this space.

Charles Powell, MD, director, Mount Sinai-National Jewish Health Respiratory Institute, sheds light on what he feels oncologists should be tackling in the future of treating patients with lung cancer.

The c-MET inhibitor capmatinib (INC280) demonstrated early signals of efficacy with an overall response rate of 20% when administered to patients with advanced c-MET–dysregulated non–small cell lung cancer.

Joel Neal, MD, PhD, assistant professor of Medicine (Oncology), Stanford University Medical Center, discusses exciting advancements in the field of lung cancer over the past few years.

Laurie E. Gaspar, MD, professor, Radiation Oncology, University of Colorado Denver, discusses a survey she conducted for physicians on the use of prophylactic cranial irradiation for patients with limited small cell lung cancer.

Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, regent, International Association for the Study of Lung Cancer (IASLC) discusses updated efficacy findings from the BIRCH trial, which was a phase II study of atezolizumab (Tecentriq) for patients with PD-L1–selected advanced non–small cell lung cancer (NSCLC). Wakelee discussed these findings during an interview at the 2016 IASLC Multidisciplinary Symposium on Thoracic Oncology.

Fred R. Hirsch, MD, PhD, professor of Medicine, University of Colorado Denver, CEO, the International Association for the Study of Lung Cancer (IASLC), discusses the value of PD-L1 assays for patients with non–small cell lung cancer. Hirsch shared his during an interview at the 2016 IASLC Multidisciplinary Symposium on Thoracic Oncology.

Harvey I. Pass, MD, director, Thoracic Surgery, Thoracic Oncology, NYU Langone Medical Center, discusses what it means to take a personalized approach to surgery in lung cancer.

Ceritinib improved progression-free survival compared with standard chemotherapy as a first-line treatment for patients with ALK-positive non–small cell lung cancer.

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), discusses the Lung Master Protocol (Lung-MAP) Trial and how it is an example of a rational clinical design that will impact patient care. Gandara shared this insight during an interview at the 2016 IASLC Multidisciplinary Symposium on Thoracic Oncology.

James R. Jett, MD, professor of Medicine Emeritus, National Jewish Health, discusses the most frequent debates surrounding molecular testing for patients with lung cancer.

Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses the toxicity profile of the therapies used in the CheckMate-227 trial.